Twist Bioscience Corporation (TWST)
Twist Bioscience: Still Not There Yet
Twist Bioscience continues to grow revenue at a healthy pace, posting 23% year-over-year sales growth and beating EPS expectations in its most recent quarter. The company holds $255 million in cash and no long-term debt. Management also just announced a spin-off that should reduce operating expenses and cash burn rate. With the stock down more than 10% since the last time Twist Bioscience was put in the spotlight in late 2024, are the shares in the 'buy zone' yet?
Twist Bioscience: Expansion Efforts Continue To Face Challenges
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will help to reduce cash burn. The transaction attributes a fairly modest valuation to the business, though. This comes after the recent struggles of the biopharma business and a royalty sale, which suggests the biopharma business hasn't created much value so far.
Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. Thank you for standing by.
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by.
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
